Pacritinib versus best available therapy for low platelet Myelofibrosis
6 Dec 2016
Pacritinib versus best available therapy for low platelet Myelofibrosis
Dose escalation of CPI-613 with bendamustine for relapsed T Cell NHL
ASH 2016 highlights: breaking new ground in haematology
TCA cycle inhibition by CPI-613 increases chemo sensitivity in older AML patients
Azacitidine plus nivolumab against acute myeloid leukaemia
IKZF1 mutations associated with paediatric ALL
Rituximab after ASCT prolongs survival for young MCL patients
Highlights in myeloid leukaemia research from ASH 2016
Thromboembolytic risks of central venous catheters in paediatric patients
Pure erythroid leukaemias
Clinical updates for guadecitabine and vorinostat
Advances in CLL from ASH 2016